<DOC>
	<DOCNO>NCT01928888</DOCNO>
	<brief_summary>The purpose study compare efficacy safety single oral administration 1000 mg Talcid® ( study medication ) , single oral administration 10 mg famotidine single oral administration placebo ( comparator without active substance ) treating symptom acute heartburn episode . The study design collect efficacy data Talcid® patient use self-medication relief symptom acute heartburn .</brief_summary>
	<brief_title>Placebo Controlled Phase IV Study Compare Efficacy Safety Single Dose Oral Talcid , Single Dose Oral Famotidine Single Dose Placebo Patients With Acute Heartburn Episodes</brief_title>
	<detailed_description />
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Hydrotalcite</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<criteria>Male female age 18 65 year A minimum 6 month history heartburn History relief heartburn episodes selfmedication ( OTC use ) within least 2 hour Occurrence heartburn episode least twice week previous two month Severity heartburn episode least 5 11category heartburn severity scale History 'alarming symptom ' e.g . weight loss , vomit , dysphagia , anemia , hematemesis melaena History gastric ulcer gastroesophageal reflux disease require regular intermittent therapy H2antagonists proton pump inhibitor within previous year History significant gastrointestinal hemorrhage gastrointestinal surgery Gastrointestinal odynophagia ( pain swallow ) History concurrent know duodenitis , pyloric dysfunction alkaline reflux , motility disturbance , Heliobacter pylorus gastritis , cholelithiasis Pregnant lactate woman , sexually active woman childbearing potential unless use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Acute heartburn episode</keyword>
</DOC>